Dashboard
1
With a fall in Net Sales of -41.19%, the company declared Very Negative results in Jun 25
- OPERATING CASH FLOW(Y) Lowest at JPY 3,222 MM
- NET SALES(Q) At JPY 9,266 MM has Fallen at -17.71%
- PRE-TAX PROFIT(Q) At JPY -1,811 MM has Fallen at -395.07%
2
Risky -
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 111,625 Million (Small Cap)
66.00
NA
0.00%
-0.20
0.86%
1.02
Revenue and Profits:
Net Sales:
9,266 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1,492 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.7%
0%
-15.7%
6 Months
-3.64%
0%
-3.64%
1 Year
-25.51%
0%
-25.51%
2 Years
-31.67%
0%
-31.67%
3 Years
-57.29%
0%
-57.29%
4 Years
-70.72%
0%
-70.72%
5 Years
-73.67%
0%
-73.67%
Takara Bio, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.44%
EBIT Growth (5y)
-18.45%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.47
Tax Ratio
45.57%
Dividend Payout Ratio
196.64%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.86%
ROE (avg)
10.18%
Valuation key factors
Factor
Value
P/E Ratio
66
Industry P/E
Price to Book Value
0.82
EV to EBIT
28.90
EV to EBITDA
9.70
EV to Capital Employed
0.76
EV to Sales
1.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2.63%
ROE (Latest)
1.23%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
9,266.00
15,757.00
-41.19%
Operating Profit (PBDIT) excl Other Income
-436.00
4,840.00
-109.01%
Interest
117.00
5.00
2,240.00%
Exceptional Items
29.00
-349.00
108.31%
Consolidate Net Profit
-1,492.00
2,434.00
-161.30%
Operating Profit Margin (Excl OI)
-193.80%
237.10%
-43.09%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -41.19% vs 65.45% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -161.30% vs 229.61% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
45,039.00
43,505.00
3.53%
Operating Profit (PBDIT) excl Other Income
6,744.00
8,024.00
-15.95%
Interest
20.00
23.00
-13.04%
Exceptional Items
-458.00
-207.00
-121.26%
Consolidate Net Profit
1,087.00
1,510.00
-28.01%
Operating Profit Margin (Excl OI)
50.20%
69.00%
-1.88%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 3.53% vs -44.33% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -28.01% vs -90.59% in Mar 2024
About Takara Bio, Inc. 
Takara Bio, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






